[Special Stock] Beom Hanwha Group Follows M2N and Sillajen with Myungmoon Pharmaceutical... Expected to Foster 'Second Celltrion-Healthcare'

[Asia Economy Reporter Hyungsoo Park] M2N is showing strong performance. The news that it has been selected as the preferred bidder for the sale of Myungmoon Pharmaceutical appears to be influencing its stock price.

As of 11:24 AM on the 2nd, M2N is trading at 11,450 KRW, up 14.5% from the previous day.

M2N is expected to leap forward as a comprehensive pharmaceutical and bio company by acquiring Myungmoon Pharmaceutical following SillaJen. The industry expects that once the acquisition is finalized, M2N will establish a strong position in the domestic pharmaceutical and bio industry.

According to the pharmaceutical and bio industry, M2N has been selected as the preferred bidder for the sale of Myungmoon Pharmaceutical and is currently conducting due diligence for the acquisition. M2N stated, "It is true that we have been selected as the preferred bidder for Myungmoon Pharmaceutical," but added, "There are no further specific details to disclose."

The acquisition of Myungmoon Pharmaceutical follows the acquisition of the bio company SillaJen in July, marking the purchase of a pharmaceutical manufacturing company that generates revenue. The industry interprets this as M2N designating the pharmaceutical and bio business as a future core business.

SillaJen is expected to develop multiple bio new drugs using its oncolytic virus platform technology, while Myungmoon Pharmaceutical is anticipated to handle synthetic drugs. The pharmaceutical industry expects synergy through a business model similar to that of Celltrion and Celltrion Healthcare involving SillaJen and Myungmoon Pharmaceutical. Since SillaJen has secured numerous new drug candidates through its oncolytic virus platform and Myungmoon Pharmaceutical holds various drug distribution rights, there is also speculation about the possibility of an internal swap deal.

M2N is a company under the Hanwha conglomerate, led by Chairman Seo Hong-min, brother-in-law of Hanwha Group Chairman Kim Seung-yeon. Its affiliate Leadcorp is well known.

This content was produced with the assistance of AI translation services.